imun_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 9, 2013
Commission File #: 000-53723
TAURIGA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Florida
(State or other jurisdiction of incorporation)
65-1102237
(IRS Employer Identification Number)
39 Old Ridgebury Road
Danbury, Connecticut 06180
(Address of principal US executive offices)
Tel: (917) 796-9926
(Registrant’s telephone number)
Immunovative, Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.03 – AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE FISCAL YEAR
Effective on April 9, 2013, Tauriga Sciences, Inc. (the “Company”) completed the process to change its name from “Immunovative, Inc.” to “Tauriga Sciences, Inc.” A copy of the Articles of Amendment to the Articles of Incorporation is attached to this Current Report on Form 8-K as Exhibit 3.1
ITEM 9.01 – FINANCIAL STATEMENTS AND EXHIBITS.
| Exhibit No. |
|
Description |
| |
|
|
|
|
|
Articles of Amendment to Articles of Incorporation
|
| |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
TAURIGA SCIENCES, INC.
|
|
| |
|
|
|
|
|
By:
|
/s/ Seth M. Shaw |
|
| |
|
Seth M. Shaw
|
|
| |
|
Chief Executive Officer
|
|
| |
|
|
|
